

COVAX: KEY STRATEGIC ISSUES

BOARD MEETING


Thabani Maphosa, Derrick Sim

7-8 December 2022, Geneva, Switzerland

Progression from COVAX in 2022-2023 to Gavi-supported COVID-19 programme from 2024

Today: COVAX in transition


2024 onwards: Potential Gavi supported C19 Programme



⊕ Additional doses/ newer products via PVP for worst case scenario

⊕ Reactive strategy for worst case scenario

Gavi's COVID-19 vaccine delivery funding targets high-risk population, amongst other objectives to support countries scale C19 vaccines



Gavi's COVID-19 response in 2023

WHO Global
COVID-19
Vaccination
Strategy in a
Changing
World (July 2022)



1. Sustain and enhance momentum to reduce mortality and morbidity, protect the health systems, and resume socio-economic activities with existing vaccines
2. Accelerate development and access to improved vaccines to achieve durable, broadly protective immunity, and reduce transmission.

Goals for
Gavi's COVID-
19 response
in 2023



1. To **support AMC participants throughout 2023** to meet their ambitions with a particular emphasis on expanding protection for higher risk populations, including with boosters, and in line with the evolving product and policy landscape
2. To **transition towards established Alliance processes** based on global pandemic trajectory while retaining capacity to respond to the WHO worst-case scenario through the Pandemic Vaccine Pool and enhancing preparedness for future pandemics (as part of the transition to Gavi 5.1)

Objectives

1 Supply

- Meet **evolving country demand** in a timely manner and mitigate supply risk through management of a sufficiently diverse portfolio
- **Secure early access to VCVs**, especially for higher risk populations
- Promote the establishment of stable, **healthy COVID-19 vaccine markets**
- **Rapidly respond in the event of the WHO worst-case scenario**, leveraging the PVP


2 Delivery support

- Advocate for and support all AMC participants to **expand protection and provide boosters to the higher priority user group**
- **Provide transitional support for primary vaccination and boosters**
- Offer **concerted support for low-coverage** countries

3 Integration

- Support **programmatic integration** of COVID-19 vaccination to strengthen routine immunisation and COVID-19 delivery
- **Integrate the COVAX organisation** with Gavi, in transition to Gavi 5.1
- Leverage **COVAX investments and embed lessons learned** for pandemic preparedness and system strengthening (as part of transition to Gavi 5.1)

Evolution of specific initiatives in 2023



Guidance

The Gavi Alliance Board is requested to **provide guidance** on Gavi's planned response to the COVID-19 pandemic in 2023, including the goals:

- a) To support AMC participants throughout 2023 to meet their ambitions with a particular emphasis on expanding protection for higher risk populations, including with boosters, and in line with the evolving product and policy landscape;
- b) To transition toward established Alliance processes based on the global pandemic trajectory while retaining capacity to respond to the WHO worst-case scenario through the Pandemic Vaccine Pool and enhancing preparedness for the next pandemic (as part of the transition to Gavi 5.1).

Thank you